Inhibrx Biosciences Files S-1 for Public Offering

TL;DR

Inhibrx Bio just filed an S-1, looks like they're gearing up for an IPO. Big news for biotech investors.

AI Summary

Inhibrx Biosciences, Inc. filed an S-1 form on June 11, 2024, indicating a public offering. The company, formerly known as Ibex SpinCo, Inc. until January 11, 2024, is based in La Jolla, CA. The filing details their financial position as of March 31, 2024, and the fiscal year ending December 31, 2023, with specific figures for common stock, additional paid-in capital, and retained earnings.

Why It Matters

This S-1 filing signals Inhibrx Biosciences' intent to raise capital through a public offering, which could significantly impact its growth and development in the biotechnology sector.

Risk Assessment

Risk Level: medium — As a biotechnology company filing an S-1, Inhibrx is likely in the early stages of development, carrying inherent risks associated with drug discovery and regulatory approval.

Key Numbers

• 2024-03-31 — Reporting Date (Financials as of this date)
• 2023-12-31 — Fiscal Year End (End of the previous fiscal year)

Key Players & Entities

• Inhibrx Biosciences, Inc. (company) — Filer of the S-1 document
• Ibex SpinCo, Inc. (company) — Former name of Inhibrx Biosciences, Inc.
• 20240611 (date) — Date of filing
• LA JOLLA, CA (location) — Company headquarters

FAQ

Key Financial Figures

• $0.0001 — es, Inc., or the Company, common stock, $0.0001 par value per share, or Common Stock, i
• $100 — Company may receive up to approximately $100 in aggregate gross proceeds from the ex
• $16.65 — rted sale price of our Common Stock was $16.65 per share. We are an "emerging growth
• $1.235 billion — e Act, our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of n
• $1.0 billion — ed $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-ye
• $700 million — ock held by non-affiliates is less than $700 million and our annual revenue is less than $10
• $100 million — ion and our annual revenue is less than $100 million during the most recently completed fisc
• $250 million — ock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than

Filing Documents

• inhibrx-20240611.htm (S-1) — 3589KB
• inhibrxbiosciences-sx1ex10.htm (EX-FILING FEES) — 21KB
• inhibrxbiosciences-sx1ex51.htm (EX-5.1) — 11KB
• exhibit104-inhibrxbioscien.htm (EX-10.4) — 166KB
• exhibit105-inhibrxbioscien.htm (EX-10.5) — 166KB
• exhibit106-inhibrxbioscien.htm (EX-10.6) — 166KB
• exhibit211-listofsubsidiar.htm (EX-21.1) — 1KB
• exhibit231-bdoinhibrxincco.htm (EX-23.1) — 2KB
• exhibit232-bdoinhibrxbiosc.htm (EX-23.2) — 2KB
• image_01.jpg (GRAPHIC) — 13KB
• image_02.jpg (GRAPHIC) — 13KB
• image_0a.jpg (GRAPHIC) — 13KB
• image_0b.jpg (GRAPHIC) — 8KB
• image_11.jpg (GRAPHIC) — 1KB
• image_12.jpg (GRAPHIC) — 1KB
• image_1a.jpg (GRAPHIC) — 1KB
• image_1b.jpg (GRAPHIC) — 11KB
• inhibrx-20240611_g1.jpg (GRAPHIC) — 163KB
• inhibrx-20240611_g2.jpg (GRAPHIC) — 159KB
• inhibrx-20240611_g3.jpg (GRAPHIC) — 43KB
• inhibrx-20240611_g4.jpg (GRAPHIC) — 138KB
• inhibrx-20240611_g5.jpg (GRAPHIC) — 41KB
• 0002007919-24-000011.txt ( ) — 14471KB
• inhibrx-20240611.xsd (EX-101.SCH) — 75KB
• inhibrx-20240611_cal.xml (EX-101.CAL) — 128KB
• inhibrx-20240611_def.xml (EX-101.DEF) — 420KB
• inhibrx-20240611_lab.xml (EX-101.LAB) — 557KB
• inhibrx-20240611_pre.xml (EX-101.PRE) — 692KB
• inhibrx-20240611_htm.xml (XML) — 1237KB

Risk Factors

Risk Factors 10 Cautionary Note Regarding Forward-Looking Statements 56

Use of Proceeds

Use of Proceeds 58 Market Information 58 Dividend Policy 58

Business

Business 59 Capitalization 102 Unaudited Pro Forma Condensed Consolidated Financial Statements 103

Management's Discussion and Analysis of Financial Condition and Results of Operations of Inhibrx, Inc

Management's Discussion and Analysis of Financial Condition and Results of Operations of Inhibrx, Inc. 114

Management's Discussion and Analysis of Financial Condition and Results of Operations of Inhibrx Biosciences, Inc

Management's Discussion and Analysis of Financial Condition and Results of Operations of Inhibrx Biosciences, Inc. 131 Corporate Governance and Management 147 D irector Compensation 153

Executive Compensation

Executive Compensation 154 Certain Relationships and Related Party Transactions 162

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 164 Selling Stockholders 166 Plan of Distribution 168 Description of Our Securities to be Registered 170 Legal Matters 175 Experts 175 Where You Can Find More Information 175 i ABOUT THIS PROSPECTUS Unless the context otherwise requires or as otherwise noted, we use the terms "Company," "we," "us," and "our" in this prospectus to refer to Inhibrx Biosciences, Inc. and its subsidiaries taken as a whole. You should rely only on the information contained in this prospectus. We have not, and the selling stockholders have not, authorized anyone to provide you with additional or different information. These securities are not being offered in any jurisdiction where the offer is not permitted. You should assume that the information in this prospectus is accurate only as of the date of the document regardless of the time of delivery of this prospectus or of any sale of our Common Stock. INDUSTRY AND MARKET DATA Unless otherwise indicated, information in this prospectus concerning economic conditions, our industry, our markets and our competitive position is based on a variety of sources, including information from third-party industry analysts and publications and our own estimates and research. Some of the industry and market data contained in this prospectus are based on third-party industry publications. This information involves a number of assumptions, estimates and limitations. The industry publications, surveys and forecasts and other public information generally indicate or suggest that their information has been obtained from sources believed to be reliable. We believe this information is reliable as of the applicable date of its publication, however, we have not independently verified the accuracy or completeness of the information included in or assumptions relied on in these third-party publications. In addition, the market and industry data and forecasts that may be inclu

View Full Filing

View this S-1 filing on SEC EDGAR